Feature Article

Addressing Cardiovascular Risks in Psoriasis: Guidance for Clinical Practice


Psoriasis is often comorbid with cardiovascular disorders and tends to have a dose-response relationship with its metabolic comorbidities.

The relative risk for healthcare-associated infections has decreased in the last 15 years due to improvements in awareness of risk associated with devices, infection control, and evidence-based practice regarding use of devices.

Latest News


Inverse Link for Mediterranean Diet Score, Severe Psoriasis

August 14, 2018

Patients with severe psoriasis have low levels of adherence to the Mediterranean diet.


Lower Real-World Drug Survival for Apremilast in Psoriasis vs Clinical Trials

By August 09, 2018

Having received prior treatment might have an effect on drug survival rates.


Ixekizumab Superior to Ustekinumab for Clearing Psoriasis Plaques

August 09, 2018

Injection site reactions did occur more frequently in the ixekizumab group compared with the ustekinumab group.


IDEOM Group Names 6 Core Domains for Psoriasis Clinical Trials

By August 02, 2018

The IDEOM group has determined 6 core domains that should be considered mandatory for all future clinical trials for psoriasis therapies.


Prevalence of Psoriatic Arthritis Quantified in Patients With Psoriasis

By August 01, 2018

Researchers sought to estimate the occurrence of psoriatic arthritis in patients with psoriasis.


Physician's Global Assessment Reliable for Evaluating Disease Activity in Psoriatic Arthritis

By July 16, 2018

Researchers sought to assess the reliability of the PGA for musculoskeletal and dermatologic manifestations in patients with psoriatic arthritis.


Early, Sustained Improvements With Apremilast in Biologic-Naive Psoriatic Arthritis

By July 13, 2018

In biologic-naive patients with psoriatic arthritis who are treated with apremilast, early onset of effect was observed across disease PsA manifestations.


Similar Quality of Life Reported in Rheumatoid Arthritis, Psoriatic Arthritis

By July 13, 2018

Health-related quality of life was similar in patients with rheumatoid arthritis and psoriatic arthritis.


More Research Needed on S aureus Colonization in Psoriasis

By July 05, 2018

Controlled studies to evaluate the benefits of a universal or targeted decolonization program in patients with psoriasis is warranted.


Ixekizumab Effective for Long-Term Treatment of Plaque Psoriasis

By July 04, 2018

Similar response rates were observed in patients with baseline scalp, nail, or palmoplantar involvement.

Sign up for Newsletters